GHB Withdrawal: Symptoms, Timeline, and Why You Need Medical Help

GHB withdrawal is a medical emergency. Unlike alcohol, where symptoms typically begin 6 to 24 hours after the last drink, GHB withdrawal can start within 1 to 6 hours of the last dose. Seizures are well-documented. Delirium occurs in 30 to 50% of hospitalized cases. People have died. If you or someone you know uses GHB or GBL regularly and needs to stop, or loses access unexpectedly, this is not something to manage at home.

Quick answers

How soon does GHB withdrawal start? Symptoms can begin within 1 to 6 hours of the last dose. GHB has a half-life of roughly 30 to 60 minutes, one of the shortest of any dependence-forming substance. The brain starts compensating almost immediately after the drug clears.

Can you have a seizure from GHB withdrawal? Yes. Seizures are well-documented and typically occur within the first 24 to 48 hours. They are not rare edge cases. Any person with significant GHB dependence who stops abruptly is at real risk.

Is GHB withdrawal more dangerous than alcohol withdrawal? In clinical terms, it is at least as dangerous and in some ways harder to treat. The onset is faster, the delirium can be more severe, and the standard medications used for alcohol withdrawal (benzodiazepines) provide only partial and inconsistent relief for GHB withdrawal.

How long does GHB withdrawal last? Acute physical symptoms typically resolve over 5 to 15 days. Insomnia can persist for 1 to 2 months after the physical symptoms pass.

What is GBL and is it different? GBL (gamma-butyrolactone) is a prodrug that converts to GHB in the body within minutes of ingestion. It is sold as an industrial solvent and used as a substitute for GHB. GBL doses are NOT interchangeable with GHB doses. GBL has a roughly 0.75:1 effective ratio compared to GHB by weight, meaning a smaller volume produces the same effect. Treating them as equivalent and dosing GBL at GHB amounts is dangerous.

Why GHB withdrawal is different from other drug withdrawals

GHB works primarily as a GABA-B receptor agonist. GABA (gamma-aminobutyric acid) is the brain’s main inhibitory neurotransmitter. When you activate GABA-B receptors repeatedly over days or weeks, the brain compensates by downregulating those receptors, reducing their sensitivity and density to maintain balance.

When GHB is suddenly removed, that compensatory downregulation leaves the brain without its normal inhibitory tone. The result is CNS hyperexcitability: neurons firing too easily, too often, with nothing dampening them. This is the same basic mechanism behind alcohol withdrawal and benzodiazepine withdrawal, but with important differences.

First, onset is dramatically faster. Alcohol withdrawal begins 6 to 24 hours after the last drink because alcohol lingers in the body. GHB’s half-life is 30 to 60 minutes. Within a few hours of the last dose, blood levels are near zero and the withdrawal process has already started. People who dose every 2 to 4 hours around the clock have essentially never given their brains a break, and when dosing stops, the shift is abrupt and severe.

Second, the receptor mechanism is different from most clinical treatments. Standard withdrawal medications like benzodiazepines work at GABA-A receptors. GHB acts at GABA-B receptors. These are related but distinct systems. Benzos provide some cross-stabilization through general CNS sedation, but they do not directly replace what GHB was doing. This is why GHB withdrawal often requires extreme benzodiazepine doses that would be sedating in most other contexts, and why some cases don’t respond to benzos at all.

The withdrawal timeline

1 to 6 hours: The first symptoms appear quickly. Insomnia, anxiety, sweating, and tremor are typical early signs. For someone who uses GHB regularly around the clock, these can begin before they would normally take their next dose.

6 to 24 hours: Symptoms intensify. Autonomic instability becomes more pronounced: heart rate rises (tachycardia), blood pressure increases (hypertension), sweating becomes heavy (diaphoresis). These are signs the nervous system is becoming dysregulated.

24 to 72 hours: peak severity. This window is the most dangerous. Autonomic instability is at its worst. Confusion appears. Many people cannot tell where they are or what is happening.

24 to 96 hours: delirium risk. Delirium, characterized by disorientation, psychosis, and severe agitation, occurs in an estimated 30 to 50% of hospitalized GHB withdrawal cases. This is not just being “out of it.” Delirium from stimulant withdrawal can cause people to become combative, injure themselves, or deteriorate quickly without intervention. In a 2004 case series of seven severe GHB withdrawal cases, all seven required ICU-level care (PMID 14976275).

Seizures are most likely in the first 24 to 48 hours, though they can occur throughout the acute phase.

5 to 15 days: Acute somatic symptoms (physical symptoms) typically resolve within this window, though the exact duration depends heavily on how long and how heavily someone has been using.

Weeks to months: Insomnia is often the most persistent symptom and can continue for 1 to 2 months after the physical withdrawal resolves. This extended sleep disruption is a significant relapse risk.

Who is at risk

Daily, around-the-clock users. GHB’s short duration, typically 2 to 4 hours per dose, means that recreational use at festivals or parties does not reliably cause dependence. The pattern that does cause dependence is dosing every 2 to 4 hours through the day and night to maintain effects or avoid early withdrawal symptoms. Some people develop this pattern within weeks. A 2001 study of 42 dependent GHB users found a mean daily dose of 34 grams per day (PMID 11727882), but dependence can develop at much lower doses with sufficient frequency.

GBL users. Because GBL converts to GHB rapidly, it creates the same dependence. GBL users are at particular risk if they don’t understand that GBL doses cannot be treated as equivalent to GHB. A “normal” GBL dose by weight is lower than a GHB dose. Someone accustomed to dosing GBL who switches to GHB and uses GHB amounts may overdose; someone who attempts GHB amounts of GBL may also overdose for the same reason in reverse.

People who lose supply unexpectedly. Hospitalization for an unrelated reason, a supplier going dry, or being in a situation where dosing becomes impossible can trigger withdrawal without warning or preparation. Medical staff treating someone for an injury or illness may not know the person is GHB-dependent, and withdrawal can begin before anyone realizes what’s happening.

People who think they can push through at home. GHB withdrawal looks manageable in its first few hours. The real danger window is 24 to 72 hours in, by which point a person in severe withdrawal may not be able to accurately assess how badly they’re deteriorating.

Treatment: what actually works

All current treatment evidence for GHB withdrawal is based on case series and case reports. There are no randomized controlled trials. This is Tier 8 evidence, the lowest tier, because conducting controlled trials on severe withdrawal syndromes is ethically and logistically difficult. What we have is this:

Benzodiazepines are first-line treatment by analogy with alcohol withdrawal. They provide general CNS sedation and reduce seizure risk through GABA-A activity. The problem is that they don’t directly substitute for GABA-B activity. Case series document patients requiring equivalent doses of 200 mg or more of diazepam per day, many times the typical anxiolytic dose, to achieve adequate sedation. Response is partial and inconsistent (PMID 11574793).

Baclofen is a GABA-B agonist, the same receptor system GHB acts on. Mechanistically, it makes more sense as a treatment than benzos. Case reports describe successful rescue in patients who did not respond to benzodiazepines. There are no RCTs, but baclofen is increasingly recognized as a critical tool in severe cases (PMID 18841188).

Pharmaceutical GHB tapering is used in some European countries where GHB (sodium oxybate) is available by prescription. A slow, structured taper allows the brain to gradually recalibrate rather than experiencing abrupt withdrawal. This approach is not available in the United States for this purpose.

ICU-level care is required for severe cases. The 2004 McDonough case series found that all seven severe GHB withdrawal cases required intensive care admission (PMID 14976275). This is not a failure of medicine; it reflects the physiological intensity of severe GHB withdrawal.

Home management is not a viable option for anyone with significant dependence. The speed of onset, the severity of potential complications, and the unpredictability of response to any available treatment mean that self-managing GHB withdrawal at home carries real risk of death.

If you or someone you know needs to stop

Do not stop cold turkey without medical support. For someone dosing regularly throughout the day, abrupt cessation without medical oversight is dangerous. The seizure window begins within hours.

Go to the emergency department, or call emergency services. Be direct: tell them about GHB or GBL use, how often, and the approximate dose. Medical staff cannot tailor treatment without this information. There is no legal obligation to provide this information, but doing so is the difference between appropriate treatment and a missed diagnosis.

If you’re trying to reduce use rather than stop entirely, that’s a slower and safer path than cold turkey, but tapering GHB is complicated by its short half-life, and doing it without medical guidance still carries risk. A physician familiar with substance use medicine can help structure a taper or arrange pharmaceutical support.

If someone collapses or has a seizure, call emergency services immediately. Put them in the recovery position if they are unconscious but breathing. Do not leave them alone.

Expect the insomnia. Even after the acute phase passes, poor sleep for weeks to months is common. Having a plan for that period, including medical support if needed, reduces the risk of relapse driven by exhaustion.

For background on GHB’s pharmacology, standard dosing, and overdose signs, see our GHB harm reduction guide. For information on interactions between GHB and other substances, see our drug interaction checker.

Sources: PMID 11574793 | PMID 11727882 | PMID 14976275 | PMID 18841188